Kravchenko I, Rudyk Iu, Medentseva O
State Institution "L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine", Kharkov, Ukraine.
Georgian Med News. 2021 Sep(318):165-171.
Over the past decades, there has been an active scientific search for drugs that can increase myocardial contractility and improve the course of heart failure. Omecamtiv Mecarbil, a drug from the group of cardiac myosin activators, heads the list of applicants for clinical use. The article presents the results of several randomized clinical trials which studied the efficacy and safety of Omecamtiv Mecarbil in heart failure: ATOMIC-AHF, COSMIC-HF and GALACTIC-HF. ATOMIC-AHF showed a tendency to reduce the risk of developing supraventricular and ventricular arrhythmias in heart failure. COSMIC-HF has proven the ability of Omecamtiv Mecarbil to improve the quality of life of patients with heart failure. GALACTIC-HF may be a turning point in the medical treatment of heart failure. For the first time, clinical evidence of the ability of the selective cardiac myosin activator Omecamtiv Mecarbil to improve myocardial contractile function, reduce the severity of symptoms of heart failure and reduce the risk of cardiovascular death was obtained.
在过去几十年里，一直在积极开展科学研究，寻找能够增强心肌收缩力并改善心力衰竭病程的药物。心肌肌球蛋白激活剂类药物omecamtiv mecarbil在临床应用候选药物中名列前茅。本文介绍了几项随机临床试验的结果，这些试验研究了omecamtiv mecarbil治疗心力衰竭的疗效和安全性：ATOMIC-AHF、COSMIC-HF和GALACTIC-HF。ATOMIC-AHF显示出降低心力衰竭患者发生室上性和室性心律失常风险的趋势。COSMIC-HF已证明omecamtiv mecarbil能够改善心力衰竭患者的生活质量。GALACTIC-HF可能是心力衰竭药物治疗的一个转折点。首次获得了选择性心肌肌球蛋白激活剂omecamtiv mecarbil能够改善心肌收缩功能、减轻心力衰竭症状严重程度并降低心血管死亡风险的临床证据。
